Florestan J. Koll, Alina Schwarz, Jens Köllermann, Séverine Banek, Luis Kluth, Clarissa Wittler, Katrin Bankov, Claudia Döring, Nina Becker, Felix Chun, Peter Johannes Wild, Henning Reis
- Introduction and Objective: Identifying patients that benefit from cisplatin-based adjuvant chemotherapy is a major issue in the management of muscle-invasive bladder cancer (MIBC). The purpose of this study is to correlate “luminal” and “basal” type protein expression with histological subtypes, to investigate the prognostic impact on survival after adjuvant chemotherapy and to define molecular consensus subtypes of “double negative” patients (i.e., without expression of CK5/6 or GATA3).
Materials and Methods: We performed immunohistochemical (IHC) analysis of CK5/6 and GATA3 for surrogate molecular subtyping in 181 MIBC samples. The mRNA expression profiles for molecular consensus classification were determined in CK5/6 and GATA3 (double) negative cases using a transcriptome panel with 19.398 mRNA targets (HTG Molecular Diagnostics). Data of 110 patients undergoing radical cystectomy were available for survival analysis.
Results: The expression of CK5/6 correlated with squamous histological subtype (96%) and expression of GATA3 was associated with micropapillary histology (100%). In the multivariate Cox-regression model, patients receiving adjuvant chemotherapy had a significant survival benefit (hazard ratio [HR]: 0.19 95% confidence interval [CI]: 0.1–0.4, p < 0.001) and double-negative cases had decreased OS (HR: 4.07; 95% CI: 1.5–10.9, p = 0.005). Double negative cases were classified as NE-like (30%), stroma-rich (30%), and Ba/Sq (40%) consensus molecular subtypes and displaying different histological subtypes.
MetadatenVerfasserangaben: | Florestan J. KollORCiD, Alina SchwarzGND, Jens KöllermannORCiDGND, Séverine BanekGND, Luis KluthORCiDGND, Clarissa WittlerGND, Katrin BankovORCiDGND, Claudia DöringGND, Nina Becker, Felix ChunORCiDGND, Peter Johannes WildORCiDGND, Henning ReisORCiDGND |
---|
URN: | urn:nbn:de:hebis:30:3-716648 |
---|
DOI: | https://doi.org/10.3389/fmed.2022.875142 |
---|
ISSN: | 2296-858X |
---|
Titel des übergeordneten Werkes (Englisch): | Frontiers in medicine |
---|
Verlag: | Frontiers Media |
---|
Verlagsort: | Lausanne |
---|
Dokumentart: | Wissenschaftlicher Artikel |
---|
Sprache: | Englisch |
---|
Datum der Veröffentlichung (online): | 16.06.2022 |
---|
Datum der Erstveröffentlichung: | 16.06.2022 |
---|
Veröffentlichende Institution: | Universitätsbibliothek Johann Christian Senckenberg |
---|
Datum der Freischaltung: | 24.01.2023 |
---|
Freies Schlagwort / Tag: | adjuvant chemotherapy; bladder cancer; consensus classification; double negative; immunohistochemistry; molecular subtyping |
---|
Jahrgang: | 9 |
---|
Ausgabe / Heft: | art. 875142 |
---|
Aufsatznummer: | 875142 |
---|
Seitenzahl: | 9 |
---|
Bemerkung: | The names of the repository/repositories and accession number(s) can be found below: The gene expression omnibus (GEO) with accession GSE198607 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE198607). |
---|
HeBIS-PPN: | 507150600 |
---|
Institute: | Medizin |
---|
DDC-Klassifikation: | 6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit |
---|
Sammlungen: | Universitätspublikationen |
---|
Lizenz (Deutsch): | Creative Commons - CC BY - Namensnennung 4.0 International |
---|